<DOC>
	<DOCNO>NCT02367066</DOCNO>
	<brief_summary>A study ass Pharmacodynamics oral AR-C165395XX Administration Repeated Doses 3 day Subjects Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>A Phase I Study Assess Pharmacodynamics Oral AR-C165395XX Subjects With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>A Single Centre , Double-blind , Randomised , Placebo-controlled , Cross-over Phase I Study Assess Pharmacodynamics oral AR-C165395XX Administration Repeated Doses 3 day Subjects Type 2 Diabetes Mellitus</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion Criteria Provision inform consent Male female nonchildbearing potential ( postmenopausal , and/or undergone hysterectomy and/or bilateral oophorectomy salpingectomy/tubal ligation ) age ≥18 . Patients HbA1c ≥7.5 ≤11 % enrolment visit ( Visit 1 ) ody mass index &gt; 19 &lt; 38 kg/m2 fast plasma glucose range 314 mmol/L ( 54252 mg/dL , nclusive ) morning Visit 1 . Clinical diagnosis type 2 diabetes mellitus Metformin antidiabetic treatment , least last 3 month History sign clinically significant disease disorder , opinion f investigator , may either put subject risk participation sudy , influence result subject 's ability participate study Any clinically significant abnormality clinical chemistry , haematology urinalysis result judge investigator Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) laboratory result &gt; 3x upper level normal range ( ULN ) Clinical diagnosis Type 1 diabetes mellitus and/or history diabetic ketoacidosis positive Glutamic Acid Decarboxylase Autoantibodies test ( GAD antibodies test ) . Patients treat single Insulin therapy within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>patient</keyword>
	<keyword>glycaemic control metformin</keyword>
</DOC>